We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
TODAY'S HIGH
6675
TODAY'S LOW
6568.2
52 WEEK HIGH
9285
52 WEEK LOW
6351
% of Shares Held by
All Insider
60.55%
% of Shares Held by
Institutions
25.31%
% of Float Held by
Institutions
64.16%
Number of Institutions
Holding Shares
54
MARKET CAP
15211.99 Cr.
ETERPRISE VALUE
13757.97 Cr.
NO. OF SHARES
2.30 Cr.
BOOK VALUE
966.366
DIV. YIELD
309%
DEBT
24.60 Cr.
GROSS PROFIT
1633.10 Cr.
CASH
1537.99 Cr.
REVENUE
2938.50 Cr.
REVENUE/SHARE
1275.899
| Particulars | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|
| Investments | 0 | 0 | 0 | 0 |
| Change To Liabilities | 67.10 Cr. | -1.80 Cr. | 23.30 Cr. | 12.50 Cr. |
| Total cashflows from Investing Activities | 630.80 Cr. | 276.40 Cr. | 65.70 Cr. | -73.10 Cr. |
| Net Borrowings | -6.60 Cr. | -4.60 Cr. | -4.60 Cr. | -4.60 Cr. |
| Total Cash from Financing Activities | -849 Cr. | -810 Cr. | -183.20 Cr. | -197.20 Cr. |
| Other Liabilities | 33.40 Cr. | 81 Cr. | -9.70 Cr. | -13.30 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 944.40 Cr. | 477.60 Cr. | 414.20 Cr. | 380.60 Cr. |
| Change in Cash | 340.60 Cr. | 77.50 Cr. | 294.80 Cr. | 103.60 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 558.80 Cr. | 611.10 Cr. | 412.30 Cr. | 373.90 Cr. |
| Depreciation | 65.30 Cr. | 81 Cr. | 98.30 Cr. | 100.80 Cr. |
| Other Cashflows from Investing Activities | 63.10 Cr. | 78 Cr. | 91 Cr. | 78.90 Cr. |
| Dividends Paid | -287.87 Cr. | -244.13 Cr. | -152 Cr. | -163.60 Cr. |
| Change to Inventory | -33.60 Cr. | -22.20 Cr. | 13.50 Cr. | -67.50 Cr. |
| Change to Account Receivables | 1.20 Cr. | 5.20 Cr. | -64.80 Cr. | 40.70 Cr. |
| Other Cashflows from Financing Activities | -1.80 Cr. | -1.60 Cr. | -31.20 Cr. | -33.60 Cr. |
| Change to Net Income | -520.40 Cr. | -10.90 Cr. | -64.10 Cr. | -81.80 Cr. |
| Capital Expenditures | -23 Cr. | -41.40 Cr. | -75.80 Cr. | -59.20 Cr. |
| Particulars | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 1257.60 Cr. | 677.20 Cr. | 599.90 Cr. | 609.80 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 695.90 Cr. | 633.80 Cr. | 567.60 Cr. | 522.70 Cr. |
| Selling General Administrative | 483.70 Cr. | 516.40 Cr. | 544.60 Cr. | 492.80 Cr. |
| Gross Profit | 1633.10 Cr. | 1622.90 Cr. | 1691.90 Cr. | 1598.60 Cr. |
| Ebit | 695.90 Cr. | 633.80 Cr. | 567.60 Cr. | 522.70 Cr. |
| Operating Income | 695.90 Cr. | 633.80 Cr. | 567.60 Cr. | 522.70 Cr. |
| Other Operating Expenses | 386.80 Cr. | 390.50 Cr. | 479.80 Cr. | 480.40 Cr. |
| Interest Expense | -1.80 Cr. | -1.80 Cr. | -30 Lakhs | -70 Lakhs |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 313.20 Cr. | 199.60 Cr. | 185.70 Cr. | 229.20 Cr. |
| Total Revenue | 2956.60 Cr. | 2901.90 Cr. | 3070.60 Cr. | 2770.80 Cr. |
| Total Operating Expenses | 2260.70 Cr. | 2268.10 Cr. | 2503 Cr. | 2248.10 Cr. |
| Cost of Revenue | 1323.50 Cr. | 1279 Cr. | 1378.70 Cr. | 1172.20 Cr. |
| Total Other Income Expense Net | 561.70 Cr. | 43.40 Cr. | 32.30 Cr. | 87.10 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 944.40 Cr. | 477.60 Cr. | 414.20 Cr. | 380.60 Cr. |
| Net Income Applicable to Common Shares | 944.40 Cr. | 477.60 Cr. | 414.20 Cr. | 380.60 Cr. |
| Particulars | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|
| Intangible Assets | 5.20 Cr. | 38.10 Cr. | 77.60 Cr. | 116.50 Cr. |
| Capital Surplus | 2 Cr. | 2 Cr. | 2 Cr. | 2 Cr. |
| Total Liabilities | 835.40 Cr. | 799.50 Cr. | 802.10 Cr. | 764.70 Cr. |
| Stock Holder Equity | 2225.60 Cr. | 2119 Cr. | 2442.30 Cr. | 2219.20 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 214.60 Cr. | 222.30 Cr. | 194.80 Cr. | 173.20 Cr. |
| Total Assets | 3061 Cr. | 2918.50 Cr. | 3244.40 Cr. | 2983.90 Cr. |
| Common Stock | 23 Cr. | 23 Cr. | 23 Cr. | 23 Cr. |
| Retained Earnings | 2140.50 Cr. | 2040 Cr. | 2375 Cr. | 2160.50 Cr. |
| Other Liabilities | 68.20 Cr. | 94.80 Cr. | 98.70 Cr. | 141.20 Cr. |
| Good Will | 0 | 73.10 Cr. | 73.10 Cr. | 73.10 Cr. |
| Treasury Stock | 60.10 Cr. | 54 Cr. | 42.30 Cr. | 33.70 Cr. |
| Other Assets | 576.20 Cr. | 611.10 Cr. | 599 Cr. | 637.60 Cr. |
| Cash | 1538 Cr. | 1197.40 Cr. | 1119.90 Cr. | 825.10 Cr. |
| Current Liabilities | 749.60 Cr. | 686.80 Cr. | 703.40 Cr. | 623.50 Cr. |
| Long Term Asset Charges | 0 | 0 | 0 | 0 |
| Short Long Term Debt | 0 | 0 | 0 | 0 |
| Other Stockholder Equity | 60.10 Cr. | 54 Cr. | 42.30 Cr. | 33.70 Cr. |
| Property Plant Equipment | 341.70 Cr. | 362.90 Cr. | 365.40 Cr. | 564.30 Cr. |
| Total Cur. Assets | 2137.90 Cr. | 1833.30 Cr. | 2129.30 Cr. | 1592.20 Cr. |
| Long Term Investments | 0 | 0 | 0 | 20 Lakhs |
| Net Tangible Assets | 2220.40 Cr. | 2007.80 Cr. | 2291.60 Cr. | 2029.60 Cr. |
| Short Term Investments | 0 | 0 | 0 | 0 |
| Net Receivables | 153.80 Cr. | 192.50 Cr. | 260.40 Cr. | 190.10 Cr. |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Inventory | 392.40 Cr. | 368 Cr. | 469.60 Cr. | 491.60 Cr. |
| Accounts Payable | 376.70 Cr. | 318.30 Cr. | 368.90 Cr. | 343.80 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account